Parkinson Disease — Improving Walking Ability in Parkinson Disease
Citation(s)
Baker K, Rochester L, Nieuwboer A The effect of cues on gait variability--reducing the attentional cost of walking in people with Parkinson's disease. Parkinsonism Relat Disord. 2008;14(4):314-20. Epub 2007 Nov 7.
Cunnington R, Iansek R, Bradshaw JL, Phillips JG Movement-related potentials in Parkinson's disease. Presence and predictability of temporal and spatial cues. Brain. 1995 Aug;118 ( Pt 4):935-50.
del Olmo MF, Arias P, Furio MC, Pozo MA, Cudeiro J Evaluation of the effect of training using auditory stimulation on rhythmic movement in Parkinsonian patients--a combined motor and [18F]-FDG PET study. Parkinsonism Relat Disord. 2006 Apr;12(3):155-64. Epub 2006 Feb 3.
Ford MP, Malone LA, Nyikos I, Yelisetty R, Bickel CS Gait training with progressive external auditory cueing in persons with Parkinson's disease. Arch Phys Med Rehabil. 2010 Aug;91(8):1255-61. doi: 10.1016/j.apmr.2010.04.012.
Heiderscheit BC Movement Variability as a Clinical Measure for Locomotion. Journal of Applied Biomechanics 16(4): 419-427, 2000.
Iosa M, Fusco A, Morone G, Paolucci S Development and decline of upright gait stability. Front Aging Neurosci. 2014 Feb 5;6:14. doi: 10.3389/fnagi.2014.00014. eCollection 2014. Review.
Iosa M, Morelli D, Marro T, Paolucci S, Fusco A Ability and stability of running and walking in children with cerebral palsy. Neuropediatrics. 2013 Jun;44(3):147-54. doi: 10.1055/s-0033-1336016. Epub 2013 Mar 13.
Kestenbaum M, Fahn S Safety of IPX066 , an extended release carbidopa-levodopa formulation, for the treatment of Parkinson's disease. Expert Opin Drug Saf. 2015 May;14(5):761-7. doi: 10.1517/14740338.2015.1015986. Epub 2015 Feb 19. Review.
Manns PJ, Baldwin E Ambulatory activity of stroke survivors: measurement options for dose, intensity, and variability of activity. Stroke. 2009 Mar;40(3):864-7. doi: 10.1161/STROKEAHA.108.531590. Epub 2009 Jan 15.
Rogers MW Disorders of posture, balance, and gait in Parkinson's disease. Clin Geriatr Med. 1996 Nov;12(4):825-45. Review.
Rubinstein TC, Giladi N, Hausdorff JM The power of cueing to circumvent dopamine deficits: a review of physical therapy treatment of gait disturbances in Parkinson's disease. Mov Disord. 2002 Nov;17(6):1148-60. Review.
Taborri J, Palermo E, Rossi S, Cappa P Gait Partitioning Methods: A Systematic Review. Sensors (Basel). 2016 Jan 6;16(1). pii: E66. doi: 10.3390/s16010066. Review.
Trojaniello D, Ravaschio A, Hausdorff JM, Cereatti A Comparative assessment of different methods for the estimation of gait temporal parameters using a single inertial sensor: application to elderly, post-stroke, Parkinson's disease and Huntington's disease subjects. Gait Posture. 2015 Sep;42(3):310-6. doi: 10.1016/j.gaitpost.2015.06.008. Epub 2015 Jun 25.
Yogev G, Plotnik M, Peretz C, Giladi N, Hausdorff JM Gait asymmetry in patients with Parkinson's disease and elderly fallers: when does the bilateral coordination of gait require attention? Exp Brain Res. 2007 Mar;177(3):336-46.
Parkinson App SmarTphone Aimed to Improve Walking Ability and Reduce Fall (P.A.S.T.A.)
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.